On Risk/Reward & Value:
MSB market cap is now
~ 1.5 X total assets, &
~ 2 X net assets.
which would be classified as 'undervalued'.
If a biotech play is already getting approvals, closing deals etc left, right & centre &/or massively increasing revenue, you will be paying a premium for that...
maybe 10X or 20X or 30X or 40X assets.
So it's all fair, you just need to choose which approach you prefer.
Ann: MSB Annual Financial Results and Operational Progress, page-203
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |